サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1728339

ペプチド薬物複合体市場-世界の産業規模、動向、機会、予測、製品別、タイプ別、地域別、競合別、2020年～2030年

Peptide Drug Conjugates Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Type, By Region and Competition, 2020-2030F

出版日
ページ情報
英文 185 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.36円

こちらのレポートには、数時間（ご購入金額の10%）分のアナリストへの質問／追加調査サービスが含まれております。

ペプチド薬物複合体市場-世界の産業規模、動向、機会、予測、製品別、タイプ別、地域別、競合別、2020年～2030年
出版日: 2025年05月16日
発行: TechSci Research
ページ情報: 英文 185 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

ペプチド薬物複合体の世界市場は、2024年には6億2,529万米ドルとなり、2030年までには13億4,715万米ドルに達すると予測され、予測期間中のCAGRは13.65%で成長すると予測されています。

この市場は、標的治療に対する需要の高まりとドラッグデリバリー技術の革新により、大幅な成長を遂げています。ペプチド薬物複合体（PDC）は、ペプチドの選択的標的化能力と抗がん剤の細胞毒性効力を組み合わせた新しい治療薬のクラスです。健康な組織を温存しながら病変細胞に対する特異性を向上させることにより、PDCは従来の化学療法よりも優れた安全性と有効性プロファイルを提供します。世界のがん罹患率の増加と精密医療へのシフトが、この分野の研究開発に拍車をかけています。PDCは抗体薬物複合体（ADC）に続くものとして勢いを増しており、より小さく適応性の高い分子を提供し、組織への浸透性を高め、免疫原性を低減しています。PDCの応用は、特に治療効果、毒性の低減、患者のコンプライアンス向上が最重要課題である腫瘍学において急速に拡大しています。

市場概要
予測期間 2026年～2030年
市場規模：2024年 6億2,529万米ドル
市場規模：2030年 13億4,715万米ドル
CAGR：2025年～2030年 13.65%
急成長セグメント 治療
最大市場 北米

主要な市場促進要因

がん罹患率の上昇

主要な市場課題

高い開発コスト

主要な市場動向

標的治療への注目の高まり

目次

第1章 製品概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界のペプチド薬物複合体市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • 製品別（ルテチウム、メルフルフェン、ANG1005、BT1718、CBX-12、その他のパイプライン製品）
    • タイプ別（治療、診断）
    • 企業別（2024年）
    • 地域別
  • 市場マップ

第6章 北米のペプチド薬物複合体市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 北米：国別分析
    • 米国
    • メキシコ
    • カナダ

第7章 欧州のペプチド薬物複合体市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 欧州：国別分析
    • フランス
    • ドイツ
    • 英国
    • イタリア
    • スペイン

第8章 アジア太平洋のペプチド薬物複合体市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • アジア太平洋：国別分析
    • 中国
    • インド
    • 韓国
    • 日本
    • オーストラリア

第9章 南米のペプチド薬物複合体市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 南米：国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第10章 中東・アフリカのペプチド薬物複合体市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 中東・アフリカ：国別分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦

第11章 市場力学

  • 促進要因
  • 課題

第12章 市場動向と発展

  • 最近の動向
  • 製品上市
  • 合併と買収

第13章 PESTEL分析

第14章 ポーターのファイブフォース分析

  • 業界内の競合
  • 新規参入の可能性
  • サプライヤーの力
  • 顧客の力
  • 代替品の脅威

第15章 競合情勢

  • Novartis AG.
  • Bicycle Therapeutics PLC
  • AstraZeneca PLC
  • Cybrexa Therapeutics Inc
  • Oncopeptides Inc.
  • Angiochem Inc.
  • Innovasium Soricimed Biopharma
  • Theratechnologies Inc.
  • Coherent Biopharma Co. Ltd
  • Wuxi STA

第16章 戦略的提言

第17章 調査会社について・免責事項

目次
Product Code: 16337

The Global Peptide Drug Conjugates Market was valued at USD 625.29 Million in 2024 and is projected to reach USD 1,347.15 Million by 2030, growing at a CAGR of 13.65% during the forecast period. This market is experiencing substantial growth due to rising demand for targeted therapies and innovation in drug delivery technologies. Peptide Drug Conjugates (PDCs) represent a novel class of therapeutics that combine the selective targeting ability of peptides with the cytotoxic potency of anti-cancer agents. By improving specificity toward diseased cells while sparing healthy tissue, PDCs offer a superior safety and efficacy profile over traditional chemotherapy. The increasing global burden of cancer, alongside the shift toward precision medicine, is fueling research and development in this space. PDCs have gained momentum as a follow-up to antibody-drug conjugates (ADCs), offering smaller, more adaptable molecules with enhanced tissue penetration and reduced immunogenicity. Their application is expanding rapidly, particularly in oncology, where treatment efficacy, reduced toxicity, and improved patient compliance are paramount.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 625.29 Million
Market Size 2030USD 1347.15 Million
CAGR 2025-203013.65%
Fastest Growing SegmentTherapeutic
Largest MarketNorth America

Key Market Drivers

Rising Incidence of Cancer

The escalating global incidence of cancer is a major driver of the peptide drug conjugates market. As cancer remains one of the leading causes of morbidity and mortality, there is a pressing need for therapies that are both effective and less toxic. Traditional chemotherapy often lacks precision, affecting both cancerous and healthy cells, which results in severe side effects. In contrast, PDCs are engineered for targeted delivery, directing cytotoxic agents specifically to cancer cells and thereby minimizing damage to healthy tissues.

This targeted approach improves patient outcomes and quality of life. According to recent projections from the International Agency for Research on Cancer (IARC), approximately 35 million new cancer cases are expected globally by 2050-a 77% increase from 2022 figures. This upward trend is creating strong demand for safer and more effective treatment modalities, positioning PDCs as a compelling therapeutic solution.

Key Market Challenges

High Development Costs

One of the primary challenges in the peptide drug conjugates market is the high cost associated with their development. The process involves complex synthesis techniques, peptide-drug conjugation, and comprehensive preclinical and clinical evaluation. These stages are time-consuming and capital-intensive, posing significant barriers for small and mid-sized companies.

Large pharmaceutical companies currently dominate this space due to their greater financial resources and ability to manage the high risks and costs. However, innovation can be fostered through strategic collaborations, public-private partnerships, and advancements in development technologies that reduce manufacturing complexity and cost. Addressing the cost barrier will be crucial to facilitating wider adoption and broader participation in the market.

Key Market Trends

The Increasing Focus on Targeted Therapies

A major trend driving growth in the PDC market is the continued shift toward targeted therapies. PDCs exemplify this trend by offering precise drug delivery that minimizes systemic toxicity. The therapeutic peptides used in PDCs can be engineered to bind selectively to overexpressed receptors on cancer cells, ensuring localized action of the therapeutic payload.

This targeted mechanism mirrors the success of monoclonal antibodies in oncology and is further enhanced by the smaller size and better tissue penetration capabilities of peptides. PDCs are now being developed not only for oncology but also for diagnostic applications, utilizing radiolabeled or imaging agents for precise disease localization. This trend underscores the expanding versatility and potential of PDCs in personalized medicine.

Key Market Players

  • Novartis AG
  • Bicycle Therapeutics PLC
  • AstraZeneca PLC
  • Cybrexa Therapeutics Inc
  • Oncopeptides Inc.
  • Angiochem Inc.
  • Innovasium Soricimed Biopharma
  • Theratechnologies Inc.
  • Coherent Biopharma Co. Ltd
  • Wuxi STA

Report Scope:

In this report, the Global Peptide Drug Conjugates Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Peptide Drug Conjugates Market, By Product:

  • Lutetium
  • Melflufen
  • ANG1005
  • BT1718
  • CBX-12
  • Other Pipeline Products

Peptide Drug Conjugates Market, By Type:

  • Therapeutic
  • Diagnostic

Peptide Drug Conjugates Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Peptide Drug Conjugates Market.

Available Customizations:

Global Peptide Drug Conjugates market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Peptide Drug Conjugates Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Lutetium, Melflufen, ANG1005, BT1718, CBX-12, Other Pipeline Products)
    • 5.2.2. By Type (Therapeutic, Diagnostic)
    • 5.2.3. By Company (2024)
    • 5.2.4. By Region
  • 5.3. Market Map

6. North America Peptide Drug Conjugates Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Type
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Peptide Drug Conjugates Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Type
    • 6.3.2. Mexico Peptide Drug Conjugates Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Type
    • 6.3.3. Canada Peptide Drug Conjugates Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Type

7. Europe Peptide Drug Conjugates Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Type
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Peptide Drug Conjugates Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Type
    • 7.3.2. Germany Peptide Drug Conjugates Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Type
    • 7.3.3. United Kingdom Peptide Drug Conjugates Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Type
    • 7.3.4. Italy Peptide Drug Conjugates Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Type
    • 7.3.5. Spain Peptide Drug Conjugates Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Type

8. Asia-Pacific Peptide Drug Conjugates Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Type
    • 8.2.3. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Peptide Drug Conjugates Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Type
    • 8.3.2. India Peptide Drug Conjugates Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Type
    • 8.3.3. South Korea Peptide Drug Conjugates Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Type
    • 8.3.4. Japan Peptide Drug Conjugates Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Type
    • 8.3.5. Australia Peptide Drug Conjugates Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Type

9. South America Peptide Drug Conjugates Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Type
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Peptide Drug Conjugates Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Type
    • 9.3.2. Argentina Peptide Drug Conjugates Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Type
    • 9.3.3. Colombia Peptide Drug Conjugates Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Type

10. Middle East and Africa Peptide Drug Conjugates Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Type
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Peptide Drug Conjugates Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Type
    • 10.3.2. Saudi Arabia Peptide Drug Conjugates Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Type
    • 10.3.3. UAE Peptide Drug Conjugates Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Type

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. PESTLE Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Product

15. Competitive Landscape

  • 15.1. Novartis AG.
    • 15.1.1. Business Overview
    • 15.1.2. Company Snapshot
    • 15.1.3. Products & Services
    • 15.1.4. Financials (As Reported)
    • 15.1.5. Recent Developments
    • 15.1.6. Key Personnel Details
    • 15.1.7. SWOT Analysis
  • 15.2. Bicycle Therapeutics PLC
  • 15.3. AstraZeneca PLC
  • 15.4. Cybrexa Therapeutics Inc
  • 15.5. Oncopeptides Inc.
  • 15.6. Angiochem Inc.
  • 15.7. Innovasium Soricimed Biopharma
  • 15.8. Theratechnologies Inc.
  • 15.9. Coherent Biopharma Co. Ltd
  • 15.10. Wuxi STA

16. Strategic Recommendation

17. About Us & Disclaimer